CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 265 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $9,913,600 | -38.1% | 640,000 | -36.3% | 2.26% | -35.1% |
| Q1 2024 | $16,009,419 | -25.3% | 1,004,355 | -20.1% | 3.49% | -38.8% |
| Q4 2023 | $21,436,112 | +52.2% | 1,257,200 | +4.3% | 5.70% | +24.4% |
| Q3 2023 | $14,086,450 | +164.0% | 1,205,000 | +4.3% | 4.58% | +325.1% |
| Q2 2020 | $5,336,000 | +32.0% | 1,155,000 | +10.0% | 1.08% | +0.7% |
| Q1 2020 | $4,043,000 | -56.6% | 1,050,000 | -42.5% | 1.07% | -58.4% |
| Q1 2019 | $9,308,000 | +221.4% | 1,825,000 | +87.2% | 2.58% | +76.1% |
| Q4 2014 | $2,896,000 | -99.9% | 975,000 | 0.0% | 1.46% | -42.0% |
| Q3 2014 | $3,237,000,000 | +92703.9% | 975,000 | -29.3% | 2.52% | -16.1% |
| Q2 2014 | $3,488,000 | +11.9% | 1,378,584 | 0.0% | 3.01% | +30.6% |
| Q1 2014 | $3,116,000 | -99.9% | 1,378,584 | +1.8% | 2.30% | +11.0% |
| Q4 2013 | $2,640,105,000 | – | 1,353,900 | – | 2.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 17,875,655 | $94,920,000 | 9.39% |
| TANAKA CAPITAL MANAGEMENT INC | 283,334 | $1,505,000 | 4.86% |
| GABLES CAPITAL MANAGEMENT INC. | 490,564 | $2,606,000 | 1.84% |
| MANGROVE PARTNERS IM, LLC | 2,508,838 | $13,322,000 | 1.61% |
| Broadfin Capital, LLC | 880,303 | $4,674,000 | 0.86% |
| Atom Investors LP | 1,012,355 | $5,376,000 | 0.37% |
| Capital Impact Advisors, LLC | 179,868 | $948,000 | 0.36% |
| KNOTT DAVID M | 151,415 | $804,000 | 0.34% |
| EMERALD ADVISERS, LLC | 1,175,958 | $6,244,000 | 0.29% |
| CADENCE CAPITAL MANAGEMENT LLC | 371,075 | $1,970,000 | 0.28% |